Drugs / INFLUENZA G1 mHA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05901636 | May 2023 → Aug 2024 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INFLUENZA G1 mHA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05901636 ↗ |
| Modality | Vaccine | “universal influenza vaccine component” PMID 41974675 ↗ Apr 2026 |
| Route | Intramuscular | “INFLUENZA G1 mHA will be administered intramuscularly.” NCT05901636 ↗ |